DSM-Firmenich stock trades at EUR 99.90, 0.8 percent below its highnarrowly near its high? no

Published on 10/12/2026 at 14:16 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

At Lang & Schwarz, DSM-Firmenich stock is EUR 99.90 on October 12, 2026, versus the EUR 100.65 Xetra close. The 52-week high is EUR 100.75.

Key points in brief

DSM-Firmenich stock stood at EUR 99.90 at Lang & Schwarz on October 12, 2026.
The price was 0.75 percent below the EUR 100.65 Xetra close of October 9, 2026.
The stock sat 0.84 percent below its EUR 100.75 52-week high.
Simply Wall St listed a EUR 95.87 consensus target on October 6, 2026.

Pop-Art-Comic mit Wissenschaftler und bunten Duftstoff-Fläschchen im Labor — dsm-firmenich AG (ISIN CH1216478797) wird als farbenfrohe Pop-Art-Comic-Szene mit Wissenschaftler und bunten Duftfläschchen inszeniert, Illustration mit AI erstellt.

DSM-Firmenich stock stood at EUR 99.90 at Lang & Schwarz on October 12, 2026 at 2:11 p.m. CEST, 0.75 percent below the EUR 100.65 Xetra close of October 9, 2026. The price was 0.84 percent below the EUR 100.75 52-week high, leaving the stock close to its recent top without a direction signal above the 1.00 percent threshold.

Trading stays below the high

The Lang & Schwarz bid was EUR 99.86 and the ask EUR 99.94 on October 12, 2026. Trading volume stood at 92,079 shares against an average volume of 699,204, while the available 52-week range extended from EUR 55.22 to EUR 100.75.

The current price was EUR 44.68 above the 52-week low, equivalent to 80.91 percent above that level. This places the stock near the upper end of its annual range, while the Xetra comparison remains the relevant day reference for the report.

Valuation sets the market frame

DSM-Firmenich had a market capitalization of EUR 24.6 billion as of October 12, 2026. Its reported P/E ratio was minus 20.71 and its trailing dividend yield was 0.03 percent, according to the current quote data.

Simply Wall St listed an analyst consensus target of EUR 95.87 on October 6, 2026. The price therefore stood 4.20 percent above that target, calculated against EUR 95.87, while the high target on the same page was EUR 117.00.

Comparison with peers

DSM-Firmenich: minus 0.75 percent, P/E minus 20.71, market capitalization EUR 24.6 billion
Givaudan (SIX, CHF): plus 0.20 percent, P/E 25.61, market capitalization CHF 31.8 billion
Symrise (Xetra, EUR): unchanged, P/E 34.66, market capitalization EUR 12.7 billion

Next reporting date

Simply Wall St lists February 18, 2027 as the next reporting earnings date. Until then, the market picture is defined by the narrow gap to the yearly high, the EUR 95.87 consensus target and the company valuation of EUR 24.6 billion.

Stock remains near its yearly high

DSM-Firmenich stock was trading at EUR 99.90 at Lang & Schwarz on October 12, 2026 at 2:11 p.m. CEST, 0.75 percent below the Xetra close of October 9, 2026 at EUR 100.65. The further course of trading is shown by the continuously updated real-time quote of DSM-Firmenich stock.